Skip to main content
SpringerLink
Log in

Hemostatic Effects of 1 mg Daily Warfarin on Post CABG Patients

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Although coronary bypass graft surgery has increased the survival and quality of life of many individuals, patients remain at risk of restenosis and thrombotic occlusion of the coronary arteries and bypass grafts. In the screening period for participation in the multicenter Post Coronary Artery Bypass Graft (Post CABG) trial, the effects of 1 mg daily warfarin were evaluated using paired patient samples collected prior to and after at least 21 days of treatment. In stable patients (n = 40; 39 males 1 female; 51–74 years old) who previously had undergone coronary artery revascularization (1–10 years), no alterations in prothrombin time, international normalized ratio (INR), prothrombin fragment 1.2, or the hemostatic risk factors factor VII antigen and coagulant activity, von Willebrand's factor, fibrinogen, tPA, or PAI-1 were associated with the 1 mg daily warfarin treatment. The observations reported here supported the Post CABG Studies Steering Committee decision to treat patients with 1–4 mg warfarin daily adjusted to achieve INRs not to exceed 2.0 consistent with low-intensity therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Center for Health Statistics. Health, United States, 1996–97 and Injury Chartbook, No. PHS 97–1232. Hyattsville, MD: Department of Health & Human Services Publication, 1997.

  2. National Hospital Discharge Survey. Vital Health Statistics, Series 13. Hyattsville, MD: Department of Health & Human Services Publication, 1990.

  3. Barboriak JJ, Batayias GE, Pintar K, Korns ME. Pathological changes in surgically removed aortocoronary vein grafts. Ann Thorac Surg 1976;21:524–527.

    Google Scholar 

  4. Campeau L, Enjalbert M, Lesperance J, et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl JMed 1984;311:1329–1332.

    Google Scholar 

  5. Neitzel GF, Barboriak JJ, Pintar K, Qureshi I. Atherosclerosis in aortocoronary bypass grafts. Morphologic study and risk factor analysis 6 to 12 years after surgery. Arteriosclerosis 1986;594–600.

  6. Solymoss BC, Nadeau P, Millette D, Campeau L. Late thrombosis of saphenous vein coronary bypass grafts related to risk factors. Circulation 1988;78(Suppl. I):I140–I143.

    Google Scholar 

  7. Poller L, McKernan A, Thomson JM, Elstein M, Hirsch PJ, Jones JB. Fixed minidose warfarin: A new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 1987;295:1309–1312.

    Google Scholar 

  8. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153–162.

    Google Scholar 

  9. Gohlke H, Gohlke-Barwolf C, Sturzenhofecker P, et al. Improved graft patency with anticoagulant therapy after aortocoronary bypass surgery; a prospective, randomized study. Circulation 1981;64(Suppl. 2):1122–1127.

    Google Scholar 

  10. van der Meer J, Hillege HL, Dunselman JM, et al. Oral anticoagulation in the prevention of one-year vein graft occlusion after aortocoronary bypass surgery: Optimal therapeutic range and practical limitations. Thromb Haemost 1994;72:676–681.

    Google Scholar 

  11. Turpie AGG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988;1:1242–1245.

    Google Scholar 

  12. Dale C, Gallus AS, Wycherley A, Langlois S, Howie D. Prevention of venous thrombosis with minidose warfarin after joint replacement. Br Med J 1991;303:224.

    Google Scholar 

  13. Fordyce MJF, Baker AS, Staddon GE. Efficacy of mixed minidose warfarin prophylaxis in total hip replacement. Br Med J 1991;303:219–220.

    Google Scholar 

  14. Dalaker K, Smith P, Arnesen H, Prydz H. Factor VII-phospholipid complex in male survivors of acute myocardial infarction. Acta Med Scand 1987;222:111–116.

    Google Scholar 

  15. Broadhurst P, Kelleher C, Hughes L, Imeson J, Raferty E. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 1990;85:169–173.

    Google Scholar 

  16. Poller L, MacCallum PK, Thomson JM, Kerns W. Reduction of factor VII coagulant activity (VIIC), a risk factor for ischaemic heart disease, by fixed dose warfarin: A double blind crossover study. Br Heart J 1990;63:231–233.

    Google Scholar 

  17. Meade TO, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986;2:533–537.

    Google Scholar 

  18. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor; a meta-analysis and review of the literature. Ann Intern Med 1993;118:963–965.

    Google Scholar 

  19. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994;14:54–59.

    Google Scholar 

  20. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo, JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635–641.

    Google Scholar 

  21. Brännström M, Jansson J-H, Boman K, Nilsson TK. Endothelial haemostatic factors may be associated with mortality in patients on long-term anticoagulant treatment. Thromb Haemost 1995;74:612–615.

    Google Scholar 

  22. Miller GJ, Bauer KA, Cooper JA, Rosenberg RD. Activation of the coagulant pathway in cigarette smokers. Thromb Haemost 1998;79:549–553.

    Google Scholar 

  23. Feinberg WM, Cornell ES, Nightingale SD, et al. Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke 1997;28:1101–1106.

    Google Scholar 

  24. Mammen EF, Koets MH, Washington BC, et al. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 1985;11:281–292.

    Google Scholar 

  25. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61–68.

    Google Scholar 

  26. Tripodi A, Cattaneo M, Molteni A, Cesana BM, Mannucci PM. Changes of prothrombin fragment 1 + 2 (F 1 + 2) as a function of increasing intensity of oral anticoagulation. Considerations on the suitability of F 1 + 2 to monitor oral anticoagulant treatment. Thromb Haemost 1998;79:571–573.

    Google Scholar 

  27. Jansson J-H, Oloffson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on longterm mortality in patients with coronary artery disease: A seven year follow-up. Circulation 1993;88:2030–2034.

    Google Scholar 

  28. Lowe GDO, Rumley A, Balendra R, Lee AJ, Tunstall-Pedoe HD. Blood rheology and haemostasis in survivors of premature myocardial infarction: A case-control study. Thromb Haemost 1993;69:796.

    Google Scholar 

  29. Smith FB, Lee AJ, Rumley A, Fowkes FGR, Lowe GDO. Tissue plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease. Atherosclerosis 1995;115:35–43.

    Google Scholar 

  30. Hamsten A, Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987;2:3–8.

    Google Scholar 

  31. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997; 350:389–396.

    Google Scholar 

  32. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633–638.

    Google Scholar 

  33. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: Randomized trial of low-intensity oral anticoagulation with warfarin and lowdose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998;351:233–241.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Loyola University Medical Center, Maywood, Illinois

    Jeanine M. Walenga, Debra Hoppensteadt & Roque Pifarré

  2. Cleveland Clinic Foundation, Cleveland, Ohio

    Michael D. Cressman

  3. University of Minnesota, Minneapolis, Minnesota

    Donald B. Hunninghake

  4. Maryland Medical Research Institute, Baltimore, Maryland

    Norma Lynn Fox

  5. Maryland Medical Research Institute, Baltimore, Maryland

    Michael L. Terrin

  6. National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA

    Jeffrey L. Probstfield

Authors
  1. Jeanine M. Walenga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Debra Hoppensteadt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roque Pifarré
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael D. Cressman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Donald B. Hunninghake
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Norma Lynn Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michael L. Terrin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jeffrey L. Probstfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Post CABG Studies Investigators
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walenga, J.M., Hoppensteadt, D., Pifarré, R. et al. Hemostatic Effects of 1 mg Daily Warfarin on Post CABG Patients. J Thromb Thrombolysis 7, 313–318 (1999). https://doi.org/10.1023/A:1008991412759

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008991412759

Search

Navigation